October 10, 2026 · Patent expires March 10, 2029

Olumiant (baricitinib): The 2029-2032 Generic Opportunity Window

Eli Lilly's once-daily oral Janus kinase (JAK) inhibitor approved for rheumatoid arthritis, alopecia areata, and COVID-19.

What we do

We track expirations like this continuously

This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.